The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database Article Swipe
Marion Pierson-Marchandise
,
Valérie Gras
,
Julien Moragny
,
Joëlle Micallef
,
Louise Gaboriau
,
Sylvie Picard
,
Gabriel Choukroun
,
Kamel Masmoudi
,
Sophie Liabeuf
·
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1111/bcp.13216
YOU?
·
· 2016
· Open Access
·
· DOI: https://doi.org/10.1111/bcp.13216
Aims Acute kidney injury (AKI) is associated with a high hospitalization rate, accelerated long‐term decline in kidney function and a high mortality rate. Adverse drug reactions (ADRs) constitute one of the most important modifiable factors in the context of AKI. Most studies of drug‐induced AKI have focused on a sole drug class. The objective of the present study was to establish a comprehensive overview of drug‐induced AKI on the basis of spontaneously reported ADRs in the French national pharmacovigilance database (FPVD). Methods We performed a case–noncase study of drug‐induced AKI. Cases corresponded to the reports of AKI recorded in the FPVD between 1 January 2015 and 31 December 2015. The noncases corresponded to all other spontaneously reported ADRs (excluding AKI) recorded in the FPVD during the same period. Data were expressed as the reporting odds ratio (ROR) and the 95% confidence interval. Results Of the 38 782 ADRs recorded in the FPVD during the study period, 3.2% were classified as cases of AKI. A total of 1254 patients experienced AKI (males: 55%; mean age ± standard deviation: 68.7 ± 15.0 years). Overall, 15.2% of the patients required renal replacement therapy. Two or more concomitantly administered drugs were involved in 66% of the cases of AKI. The most frequently implicated drug classes were antibacterial agents for systemic use (29.5%), diuretics (18.5%), agents acting on the renin–angiotensin system (16.3%), antineoplastic agents (10.2%) and anti‐inflammatory agents (5.4%). Gentamicin, eplerenone, spironolactone, candesartan, cisplatin and acyclovir had the highest RORs (>10). Conclusion A comprehensive study of a national pharmacovigilance database enabled us to identify the drug classes that most frequently induced AKI. Even though most of the identified drugs were already known to induce AKI, the present work should raise physicians' awareness of the compounds responsible for triggering this potentially life‐threatening condition.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/bcp.13216
- https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216
- OA Status
- bronze
- Cited By
- 142
- References
- 44
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2562729918
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2562729918Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/bcp.13216Digital Object Identifier
- Title
-
The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance databaseWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2016Year of publication
- Publication date
-
2016-12-21Full publication date if available
- Authors
-
Marion Pierson-Marchandise, Valérie Gras, Julien Moragny, Joëlle Micallef, Louise Gaboriau, Sylvie Picard, Gabriel Choukroun, Kamel Masmoudi, Sophie LiabeufList of authors in order
- Landing page
-
https://doi.org/10.1111/bcp.13216Publisher landing page
- PDF URL
-
https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216Direct OA link when available
- Concepts
-
Medicine, Pharmacovigilance, Acute kidney injury, Odds ratio, Internal medicine, Renal function, Context (archaeology), Database, Confidence interval, Intensive care medicine, Adverse effect, Pharmacology, Paleontology, Computer science, BiologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
142Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 15, 2024: 53, 2023: 16, 2022: 17, 2021: 14Per-year citation counts (last 5 years)
- References (count)
-
44Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2562729918 |
|---|---|
| doi | https://doi.org/10.1111/bcp.13216 |
| ids.doi | https://doi.org/10.1111/bcp.13216 |
| ids.mag | 2562729918 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/28002877 |
| ids.openalex | https://openalex.org/W2562729918 |
| fwci | 3.4495502 |
| mesh[0].qualifier_ui | Q000139 |
| mesh[0].descriptor_ui | D058186 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | chemically induced |
| mesh[0].descriptor_name | Acute Kidney Injury |
| mesh[1].qualifier_ui | Q000453 |
| mesh[1].descriptor_ui | D058186 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | epidemiology |
| mesh[1].descriptor_name | Acute Kidney Injury |
| mesh[2].qualifier_ui | Q000628 |
| mesh[2].descriptor_ui | D058186 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | therapy |
| mesh[2].descriptor_name | Acute Kidney Injury |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000293 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Adolescent |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D000328 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Adult |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D000368 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Aged |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000369 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Aged, 80 and over |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D016208 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Databases, Factual |
| mesh[8].qualifier_ui | Q000453 |
| mesh[8].descriptor_ui | D064420 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | epidemiology |
| mesh[8].descriptor_name | Drug-Related Side Effects and Adverse Reactions |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D005260 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Female |
| mesh[10].qualifier_ui | Q000453 |
| mesh[10].descriptor_ui | D005602 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | epidemiology |
| mesh[10].descriptor_name | France |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D005919 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Glomerular Filtration Rate |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D006801 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Humans |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D007677 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Kidney Function Tests |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D008297 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Male |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D008875 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Middle Aged |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D016017 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Odds Ratio |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D060735 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Pharmacovigilance |
| mesh[18].qualifier_ui | Q000706 |
| mesh[18].descriptor_ui | D017582 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | statistics & numerical data |
| mesh[18].descriptor_name | Renal Replacement Therapy |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D055815 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Young Adult |
| mesh[20].qualifier_ui | Q000139 |
| mesh[20].descriptor_ui | D058186 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | chemically induced |
| mesh[20].descriptor_name | Acute Kidney Injury |
| mesh[21].qualifier_ui | Q000453 |
| mesh[21].descriptor_ui | D058186 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | epidemiology |
| mesh[21].descriptor_name | Acute Kidney Injury |
| mesh[22].qualifier_ui | Q000628 |
| mesh[22].descriptor_ui | D058186 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | therapy |
| mesh[22].descriptor_name | Acute Kidney Injury |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000293 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Adolescent |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D000328 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Adult |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D000368 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Aged |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000369 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Aged, 80 and over |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D016208 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Databases, Factual |
| mesh[28].qualifier_ui | Q000453 |
| mesh[28].descriptor_ui | D064420 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | epidemiology |
| mesh[28].descriptor_name | Drug-Related Side Effects and Adverse Reactions |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D005260 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Female |
| mesh[30].qualifier_ui | Q000453 |
| mesh[30].descriptor_ui | D005602 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | epidemiology |
| mesh[30].descriptor_name | France |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D005919 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Glomerular Filtration Rate |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D006801 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Humans |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D007677 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Kidney Function Tests |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D008297 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Male |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D008875 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Middle Aged |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D016017 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Odds Ratio |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D060735 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Pharmacovigilance |
| mesh[38].qualifier_ui | Q000706 |
| mesh[38].descriptor_ui | D017582 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | statistics & numerical data |
| mesh[38].descriptor_name | Renal Replacement Therapy |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D055815 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Young Adult |
| type | article |
| title | The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database |
| biblio.issue | 6 |
| biblio.volume | 83 |
| biblio.last_page | 1349 |
| biblio.first_page | 1341 |
| topics[0].id | https://openalex.org/T11943 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9986000061035156 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3005 |
| topics[0].subfield.display_name | Toxicology |
| topics[0].display_name | Pharmacovigilance and Adverse Drug Reactions |
| topics[1].id | https://openalex.org/T10684 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9984999895095825 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2727 |
| topics[1].subfield.display_name | Nephrology |
| topics[1].display_name | Acute Kidney Injury Research |
| topics[2].id | https://openalex.org/T11465 |
| topics[2].field.id | https://openalex.org/fields/30 |
| topics[2].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[2].score | 0.989799976348877 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/3004 |
| topics[2].subfield.display_name | Pharmacology |
| topics[2].display_name | Drug-Induced Hepatotoxicity and Protection |
| is_xpac | False |
| apc_list.value | 4330 |
| apc_list.currency | USD |
| apc_list.value_usd | 4330 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8862317800521851 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C57658597 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8371292352676392 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1550789 |
| concepts[1].display_name | Pharmacovigilance |
| concepts[2].id | https://openalex.org/C2780472472 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7142311334609985 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q424337 |
| concepts[2].display_name | Acute kidney injury |
| concepts[3].id | https://openalex.org/C156957248 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5430031418800354 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1862216 |
| concepts[3].display_name | Odds ratio |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5104728937149048 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C159641895 |
| concepts[5].level | 2 |
| concepts[5].score | 0.47451251745224 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q108377937 |
| concepts[5].display_name | Renal function |
| concepts[6].id | https://openalex.org/C2779343474 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4551723599433899 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q3109175 |
| concepts[6].display_name | Context (archaeology) |
| concepts[7].id | https://openalex.org/C77088390 |
| concepts[7].level | 1 |
| concepts[7].score | 0.41946446895599365 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q8513 |
| concepts[7].display_name | Database |
| concepts[8].id | https://openalex.org/C44249647 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4113962948322296 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q208498 |
| concepts[8].display_name | Confidence interval |
| concepts[9].id | https://openalex.org/C177713679 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3663730025291443 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q679690 |
| concepts[9].display_name | Intensive care medicine |
| concepts[10].id | https://openalex.org/C197934379 |
| concepts[10].level | 2 |
| concepts[10].score | 0.36186715960502625 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2047938 |
| concepts[10].display_name | Adverse effect |
| concepts[11].id | https://openalex.org/C98274493 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3500722050666809 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[11].display_name | Pharmacology |
| concepts[12].id | https://openalex.org/C151730666 |
| concepts[12].level | 1 |
| concepts[12].score | 0.0 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q7205 |
| concepts[12].display_name | Paleontology |
| concepts[13].id | https://openalex.org/C41008148 |
| concepts[13].level | 0 |
| concepts[13].score | 0.0 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[13].display_name | Computer science |
| concepts[14].id | https://openalex.org/C86803240 |
| concepts[14].level | 0 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[14].display_name | Biology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8862317800521851 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/pharmacovigilance |
| keywords[1].score | 0.8371292352676392 |
| keywords[1].display_name | Pharmacovigilance |
| keywords[2].id | https://openalex.org/keywords/acute-kidney-injury |
| keywords[2].score | 0.7142311334609985 |
| keywords[2].display_name | Acute kidney injury |
| keywords[3].id | https://openalex.org/keywords/odds-ratio |
| keywords[3].score | 0.5430031418800354 |
| keywords[3].display_name | Odds ratio |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5104728937149048 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/renal-function |
| keywords[5].score | 0.47451251745224 |
| keywords[5].display_name | Renal function |
| keywords[6].id | https://openalex.org/keywords/context |
| keywords[6].score | 0.4551723599433899 |
| keywords[6].display_name | Context (archaeology) |
| keywords[7].id | https://openalex.org/keywords/database |
| keywords[7].score | 0.41946446895599365 |
| keywords[7].display_name | Database |
| keywords[8].id | https://openalex.org/keywords/confidence-interval |
| keywords[8].score | 0.4113962948322296 |
| keywords[8].display_name | Confidence interval |
| keywords[9].id | https://openalex.org/keywords/intensive-care-medicine |
| keywords[9].score | 0.3663730025291443 |
| keywords[9].display_name | Intensive care medicine |
| keywords[10].id | https://openalex.org/keywords/adverse-effect |
| keywords[10].score | 0.36186715960502625 |
| keywords[10].display_name | Adverse effect |
| keywords[11].id | https://openalex.org/keywords/pharmacology |
| keywords[11].score | 0.3500722050666809 |
| keywords[11].display_name | Pharmacology |
| language | en |
| locations[0].id | doi:10.1111/bcp.13216 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S13842274 |
| locations[0].source.issn | 0306-5251, 1365-2125 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0306-5251 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | British Journal of Clinical Pharmacology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | |
| locations[0].pdf_url | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | British Journal of Clinical Pharmacology |
| locations[0].landing_page_url | https://doi.org/10.1111/bcp.13216 |
| locations[1].id | pmid:28002877 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | British journal of clinical pharmacology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/28002877 |
| locations[2].id | pmh:oai:HAL:hal-03574256v1 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306402512 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | HAL (Le Centre pour la Communication Scientifique Directe) |
| locations[2].source.host_organization | https://openalex.org/I1294671590 |
| locations[2].source.host_organization_name | Centre National de la Recherche Scientifique |
| locations[2].source.host_organization_lineage | https://openalex.org/I1294671590 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Journal articles |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | British Journal of Clinical Pharmacology, 2017, 83 (6), pp.1341-1349. ⟨10.1111/bcp.13216⟩ |
| locations[2].landing_page_url | https://u-picardie.hal.science/hal-03574256 |
| locations[3].id | pmh:oai:europepmc.org:4926697 |
| locations[3].is_oa | False |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/5427222 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5057051200 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Marion Pierson-Marchandise |
| authorships[0].countries | FR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210096553 |
| authorships[0].affiliations[0].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[0].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[0].institutions[0].ror | https://ror.org/010567a58 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[0].institutions[0].country_code | FR |
| authorships[0].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Marion Pierson-Marchandise |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | CHU Amiens-Picardie (France) |
| authorships[1].author.id | https://openalex.org/A5016165400 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Valérie Gras |
| authorships[1].countries | FR |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210096553 |
| authorships[1].affiliations[0].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[1].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[1].institutions[0].ror | https://ror.org/010567a58 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[1].institutions[0].country_code | FR |
| authorships[1].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Valerie Gras |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | CHU Amiens-Picardie (France) |
| authorships[2].author.id | https://openalex.org/A5051814568 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-3154-5770 |
| authorships[2].author.display_name | Julien Moragny |
| authorships[2].countries | FR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210096553 |
| authorships[2].affiliations[0].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[2].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[2].institutions[0].ror | https://ror.org/010567a58 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[2].institutions[0].country_code | FR |
| authorships[2].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Julien Moragny |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | CHU Amiens-Picardie (France) |
| authorships[3].author.id | https://openalex.org/A5016176687 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-7172-7835 |
| authorships[3].author.display_name | Joëlle Micallef |
| authorships[3].countries | FR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210138220 |
| authorships[3].affiliations[0].raw_affiliation_string | INT - Institut de Neurosciences de la Timone (Faculté de Médecine - Bâtiment Neurosciences 27, Bd Jean Moulin - 13385 Marseille Cedex 05 - France) |
| authorships[3].affiliations[1].institution_ids | https://openalex.org/I4210110495 |
| authorships[3].affiliations[1].raw_affiliation_string | INS - Institut de Neurosciences des Systèmes (Faculté de Médecine - Secteur Timone - 27 boulevard Jean Moulin 13385 Marseille Cedex 05 - France) |
| authorships[3].affiliations[2].institution_ids | https://openalex.org/I4210162909 |
| authorships[3].affiliations[2].raw_affiliation_string | Service de Pharmacologie Clinique [Hôpital de la Timone - APHM] (France) |
| authorships[3].institutions[0].id | https://openalex.org/I4210162909 |
| authorships[3].institutions[0].ror | https://ror.org/05jrr4320 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210087487, https://openalex.org/I4210162909 |
| authorships[3].institutions[0].country_code | FR |
| authorships[3].institutions[0].display_name | Hôpital de la Timone |
| authorships[3].institutions[1].id | https://openalex.org/I4210138220 |
| authorships[3].institutions[1].ror | https://ror.org/043hw6336 |
| authorships[3].institutions[1].type | facility |
| authorships[3].institutions[1].lineage | https://openalex.org/I1294671590, https://openalex.org/I1294671590, https://openalex.org/I21491767, https://openalex.org/I4210096427, https://openalex.org/I4210138220 |
| authorships[3].institutions[1].country_code | FR |
| authorships[3].institutions[1].display_name | Institut de Neurosciences de la Timone |
| authorships[3].institutions[2].id | https://openalex.org/I4210110495 |
| authorships[3].institutions[2].ror | https://ror.org/019kqby73 |
| authorships[3].institutions[2].type | facility |
| authorships[3].institutions[2].lineage | https://openalex.org/I154526488, https://openalex.org/I21491767, https://openalex.org/I4210087487, https://openalex.org/I4210110495 |
| authorships[3].institutions[2].country_code | FR |
| authorships[3].institutions[2].display_name | Institut de Neurosciences des Systèmes |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Joelle Micallef |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | INS - Institut de Neurosciences des Systèmes (Faculté de Médecine - Secteur Timone - 27 boulevard Jean Moulin 13385 Marseille Cedex 05 - France), INT - Institut de Neurosciences de la Timone (Faculté de Médecine - Bâtiment Neurosciences 27, Bd Jean Moulin - 13385 Marseille Cedex 05 - France), Service de Pharmacologie Clinique [Hôpital de la Timone - APHM] (France) |
| authorships[4].author.id | https://openalex.org/A5067247480 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-1367-5109 |
| authorships[4].author.display_name | Louise Gaboriau |
| authorships[4].countries | FR |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I3018718406 |
| authorships[4].affiliations[0].raw_affiliation_string | CRPV - Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] (CHRU, 1 Place de Verdun - 59045 LILLE CEDEX - France) |
| authorships[4].institutions[0].id | https://openalex.org/I3018718406 |
| authorships[4].institutions[0].ror | https://ror.org/02ppyfa04 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I3018718406 |
| authorships[4].institutions[0].country_code | FR |
| authorships[4].institutions[0].display_name | Centre Hospitalier Universitaire de Lille |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Louise Gaboriau |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | CRPV - Centre Régional de PharmacoVigilance Nord-Pas-de-Calais [CHU Lille] (CHRU, 1 Place de Verdun - 59045 LILLE CEDEX - France) |
| authorships[5].author.id | https://openalex.org/A5088504435 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-0463-8063 |
| authorships[5].author.display_name | Sylvie Picard |
| authorships[5].countries | FR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210155724 |
| authorships[5].affiliations[0].raw_affiliation_string | Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou] (2 Rue Henri le Guilloux, 35000 Rennes - France) |
| authorships[5].institutions[0].id | https://openalex.org/I4210155724 |
| authorships[5].institutions[0].ror | https://ror.org/05qec5a53 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210155724 |
| authorships[5].institutions[0].country_code | FR |
| authorships[5].institutions[0].display_name | Centre Hospitalier Universitaire de Rennes |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Sylvie Picard |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Ponchaillou] (2 Rue Henri le Guilloux, 35000 Rennes - France) |
| authorships[6].author.id | https://openalex.org/A5057090299 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0772-5656 |
| authorships[6].author.display_name | Gabriel Choukroun |
| authorships[6].countries | FR |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4647051 |
| authorships[6].affiliations[0].raw_affiliation_string | MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (Université de Picardie Jules Verne - Centre de Recherche Universitaire en Santé (CURS) - CHU Sud - rue Renée Laennec - 80054 Amiens Cedex - France) |
| authorships[6].affiliations[1].institution_ids | https://openalex.org/I4210096553 |
| authorships[6].affiliations[1].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[6].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[6].institutions[0].ror | https://ror.org/010567a58 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[6].institutions[0].country_code | FR |
| authorships[6].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[6].institutions[1].id | https://openalex.org/I4647051 |
| authorships[6].institutions[1].ror | https://ror.org/01gyxrk03 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I4647051 |
| authorships[6].institutions[1].country_code | FR |
| authorships[6].institutions[1].display_name | Université de Picardie Jules Verne |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Gabriel Choukroun |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | CHU Amiens-Picardie (France), MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (Université de Picardie Jules Verne - Centre de Recherche Universitaire en Santé (CURS) - CHU Sud - rue Renée Laennec - 80054 Amiens Cedex - France) |
| authorships[7].author.id | https://openalex.org/A5018977565 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Kamel Masmoudi |
| authorships[7].countries | FR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210096553 |
| authorships[7].affiliations[0].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[7].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[7].institutions[0].ror | https://ror.org/010567a58 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[7].institutions[0].country_code | FR |
| authorships[7].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Kamel Masmoudi |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | CHU Amiens-Picardie (France) |
| authorships[8].author.id | https://openalex.org/A5033170314 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-5384-9006 |
| authorships[8].author.display_name | Sophie Liabeuf |
| authorships[8].countries | FR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210096553 |
| authorships[8].affiliations[0].raw_affiliation_string | CHU Amiens-Picardie (France) |
| authorships[8].affiliations[1].institution_ids | https://openalex.org/I4647051 |
| authorships[8].affiliations[1].raw_affiliation_string | MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (Université de Picardie Jules Verne - Centre de Recherche Universitaire en Santé (CURS) - CHU Sud - rue Renée Laennec - 80054 Amiens Cedex - France) |
| authorships[8].institutions[0].id | https://openalex.org/I4210096553 |
| authorships[8].institutions[0].ror | https://ror.org/010567a58 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210096553 |
| authorships[8].institutions[0].country_code | FR |
| authorships[8].institutions[0].display_name | Centre Hospitalier Universitaire Amiens-Picardie |
| authorships[8].institutions[1].id | https://openalex.org/I4647051 |
| authorships[8].institutions[1].ror | https://ror.org/01gyxrk03 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I4647051 |
| authorships[8].institutions[1].country_code | FR |
| authorships[8].institutions[1].display_name | Université de Picardie Jules Verne |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Sophie Liabeuf |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | CHU Amiens-Picardie (France), MP3CV - Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (Université de Picardie Jules Verne - Centre de Recherche Universitaire en Santé (CURS) - CHU Sud - rue Renée Laennec - 80054 Amiens Cedex - France) |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | The drugs that mostly frequently induce acute kidney injury: a case − noncase study of a pharmacovigilance database |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11943 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9986000061035156 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3005 |
| primary_topic.subfield.display_name | Toxicology |
| primary_topic.display_name | Pharmacovigilance and Adverse Drug Reactions |
| related_works | https://openalex.org/W2125179413, https://openalex.org/W2719570687, https://openalex.org/W2894377005, https://openalex.org/W2066240751, https://openalex.org/W3120767282, https://openalex.org/W2898439368, https://openalex.org/W2094484004, https://openalex.org/W3128299827, https://openalex.org/W2181320814, https://openalex.org/W3105953293 |
| cited_by_count | 142 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 15 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 53 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 16 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 17 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 14 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 10 |
| counts_by_year[6].year | 2019 |
| counts_by_year[6].cited_by_count | 5 |
| counts_by_year[7].year | 2018 |
| counts_by_year[7].cited_by_count | 9 |
| counts_by_year[8].year | 2017 |
| counts_by_year[8].cited_by_count | 2 |
| locations_count | 4 |
| best_oa_location.id | doi:10.1111/bcp.13216 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S13842274 |
| best_oa_location.source.issn | 0306-5251, 1365-2125 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0306-5251 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | British Journal of Clinical Pharmacology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_name | Wiley |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| best_oa_location.source.host_organization_lineage_names | Wiley |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | British Journal of Clinical Pharmacology |
| best_oa_location.landing_page_url | https://doi.org/10.1111/bcp.13216 |
| primary_location.id | doi:10.1111/bcp.13216 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S13842274 |
| primary_location.source.issn | 0306-5251, 1365-2125 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0306-5251 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | British Journal of Clinical Pharmacology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | |
| primary_location.pdf_url | https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13216 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | British Journal of Clinical Pharmacology |
| primary_location.landing_page_url | https://doi.org/10.1111/bcp.13216 |
| publication_date | 2016-12-21 |
| publication_year | 2016 |
| referenced_works | https://openalex.org/W2069722312, https://openalex.org/W2111704803, https://openalex.org/W2141559993, https://openalex.org/W2079079821, https://openalex.org/W2107538404, https://openalex.org/W2026274122, https://openalex.org/W2099114703, https://openalex.org/W2118884380, https://openalex.org/W2149687213, https://openalex.org/W2089374147, https://openalex.org/W1987823269, https://openalex.org/W2348528624, https://openalex.org/W2085752173, https://openalex.org/W2022467092, https://openalex.org/W2035064373, https://openalex.org/W1061955335, https://openalex.org/W2097922521, https://openalex.org/W1990654536, https://openalex.org/W2096272626, https://openalex.org/W2071060198, https://openalex.org/W2460450412, https://openalex.org/W2171132666, https://openalex.org/W2169800903, https://openalex.org/W1985069389, https://openalex.org/W2111154593, https://openalex.org/W1993769900, https://openalex.org/W1984796878, https://openalex.org/W2410605558, https://openalex.org/W2085220821, https://openalex.org/W1990691480, https://openalex.org/W2141633768, https://openalex.org/W6692456131, https://openalex.org/W1995987873, https://openalex.org/W2023243818, https://openalex.org/W1976060163, https://openalex.org/W2136932375, https://openalex.org/W4250210754, https://openalex.org/W2124815378, https://openalex.org/W1921103812, https://openalex.org/W2079433011, https://openalex.org/W146098013, https://openalex.org/W2086049425, https://openalex.org/W4299339933, https://openalex.org/W2259983755 |
| referenced_works_count | 44 |
| abstract_inverted_index.1 | 102 |
| abstract_inverted_index.A | 163, 247 |
| abstract_inverted_index.a | 8, 19, 48, 61, 84, 251 |
| abstract_inverted_index.31 | 106 |
| abstract_inverted_index.38 | 145 |
| abstract_inverted_index.Of | 143 |
| abstract_inverted_index.We | 82 |
| abstract_inverted_index.as | 131, 159 |
| abstract_inverted_index.in | 15, 35, 74, 98, 121, 149, 198 |
| abstract_inverted_index.is | 5 |
| abstract_inverted_index.of | 29, 38, 42, 54, 64, 70, 87, 95, 161, 165, 183, 200, 203, 250, 270, 287 |
| abstract_inverted_index.on | 47, 67, 222 |
| abstract_inverted_index.or | 191 |
| abstract_inverted_index.to | 59, 92, 112, 257, 277 |
| abstract_inverted_index.us | 256 |
| abstract_inverted_index.± | 174, 178 |
| abstract_inverted_index.66% | 199 |
| abstract_inverted_index.782 | 146 |
| abstract_inverted_index.95% | 139 |
| abstract_inverted_index.AKI | 44, 66, 96, 169 |
| abstract_inverted_index.The | 52, 109, 205 |
| abstract_inverted_index.Two | 190 |
| abstract_inverted_index.age | 173 |
| abstract_inverted_index.all | 113 |
| abstract_inverted_index.and | 18, 105, 137, 230, 239 |
| abstract_inverted_index.for | 214, 291 |
| abstract_inverted_index.had | 241 |
| abstract_inverted_index.one | 28 |
| abstract_inverted_index.the | 30, 36, 55, 68, 75, 93, 99, 122, 125, 132, 138, 144, 150, 153, 184, 201, 223, 242, 259, 271, 280, 288 |
| abstract_inverted_index.use | 216 |
| abstract_inverted_index.was | 58 |
| abstract_inverted_index.1254 | 166 |
| abstract_inverted_index.15.0 | 179 |
| abstract_inverted_index.2015 | 104 |
| abstract_inverted_index.3.2% | 156 |
| abstract_inverted_index.55%; | 171 |
| abstract_inverted_index.68.7 | 177 |
| abstract_inverted_index.ADRs | 73, 117, 147 |
| abstract_inverted_index.AKI) | 119 |
| abstract_inverted_index.AKI, | 279 |
| abstract_inverted_index.AKI. | 39, 89, 162, 204, 266 |
| abstract_inverted_index.Aims | 0 |
| abstract_inverted_index.Data | 128 |
| abstract_inverted_index.Even | 267 |
| abstract_inverted_index.FPVD | 100, 123, 151 |
| abstract_inverted_index.Most | 40 |
| abstract_inverted_index.RORs | 244 |
| abstract_inverted_index.drug | 24, 50, 209, 260 |
| abstract_inverted_index.have | 45 |
| abstract_inverted_index.high | 9, 20 |
| abstract_inverted_index.mean | 172 |
| abstract_inverted_index.more | 192 |
| abstract_inverted_index.most | 31, 206, 263, 269 |
| abstract_inverted_index.odds | 134 |
| abstract_inverted_index.same | 126 |
| abstract_inverted_index.sole | 49 |
| abstract_inverted_index.that | 262 |
| abstract_inverted_index.this | 293 |
| abstract_inverted_index.were | 129, 157, 196, 211, 274 |
| abstract_inverted_index.with | 7 |
| abstract_inverted_index.work | 282 |
| abstract_inverted_index.(AKI) | 4 |
| abstract_inverted_index.(ROR) | 136 |
| abstract_inverted_index.15.2% | 182 |
| abstract_inverted_index.2015. | 108 |
| abstract_inverted_index.Acute | 1 |
| abstract_inverted_index.Cases | 90 |
| abstract_inverted_index.basis | 69 |
| abstract_inverted_index.cases | 160, 202 |
| abstract_inverted_index.drugs | 195, 273 |
| abstract_inverted_index.known | 276 |
| abstract_inverted_index.other | 114 |
| abstract_inverted_index.raise | 284 |
| abstract_inverted_index.rate, | 11 |
| abstract_inverted_index.rate. | 22 |
| abstract_inverted_index.ratio | 135 |
| abstract_inverted_index.renal | 187 |
| abstract_inverted_index.study | 57, 86, 154, 249 |
| abstract_inverted_index.total | 164 |
| abstract_inverted_index.(ADRs) | 26 |
| abstract_inverted_index.French | 76 |
| abstract_inverted_index.acting | 221 |
| abstract_inverted_index.agents | 213, 220, 228, 232 |
| abstract_inverted_index.class. | 51 |
| abstract_inverted_index.during | 124, 152 |
| abstract_inverted_index.induce | 278 |
| abstract_inverted_index.injury | 3 |
| abstract_inverted_index.kidney | 2, 16 |
| abstract_inverted_index.should | 283 |
| abstract_inverted_index.system | 225 |
| abstract_inverted_index.though | 268 |
| abstract_inverted_index.(10.2%) | 229 |
| abstract_inverted_index.(5.4%). | 233 |
| abstract_inverted_index.(FPVD). | 80 |
| abstract_inverted_index.(males: | 170 |
| abstract_inverted_index.Adverse | 23 |
| abstract_inverted_index.January | 103 |
| abstract_inverted_index.Methods | 81 |
| abstract_inverted_index.Results | 142 |
| abstract_inverted_index.already | 275 |
| abstract_inverted_index.between | 101 |
| abstract_inverted_index.classes | 210, 261 |
| abstract_inverted_index.context | 37 |
| abstract_inverted_index.decline | 14 |
| abstract_inverted_index.enabled | 255 |
| abstract_inverted_index.factors | 34 |
| abstract_inverted_index.focused | 46 |
| abstract_inverted_index.highest | 243 |
| abstract_inverted_index.induced | 265 |
| abstract_inverted_index.period, | 155 |
| abstract_inverted_index.period. | 127 |
| abstract_inverted_index.present | 56, 281 |
| abstract_inverted_index.reports | 94 |
| abstract_inverted_index.studies | 41 |
| abstract_inverted_index.years). | 180 |
| abstract_inverted_index.(16.3%), | 226 |
| abstract_inverted_index.(18.5%), | 219 |
| abstract_inverted_index.(29.5%), | 217 |
| abstract_inverted_index.December | 107 |
| abstract_inverted_index.Overall, | 181 |
| abstract_inverted_index.database | 79, 254 |
| abstract_inverted_index.function | 17 |
| abstract_inverted_index.identify | 258 |
| abstract_inverted_index.involved | 197 |
| abstract_inverted_index.national | 77, 252 |
| abstract_inverted_index.noncases | 110 |
| abstract_inverted_index.overview | 63 |
| abstract_inverted_index.patients | 167, 185 |
| abstract_inverted_index.recorded | 97, 120, 148 |
| abstract_inverted_index.reported | 72, 116 |
| abstract_inverted_index.required | 186 |
| abstract_inverted_index.standard | 175 |
| abstract_inverted_index.systemic | 215 |
| abstract_inverted_index.therapy. | 189 |
| abstract_inverted_index.(>10). | 245 |
| abstract_inverted_index.acyclovir | 240 |
| abstract_inverted_index.awareness | 286 |
| abstract_inverted_index.cisplatin | 238 |
| abstract_inverted_index.compounds | 289 |
| abstract_inverted_index.diuretics | 218 |
| abstract_inverted_index.establish | 60 |
| abstract_inverted_index.expressed | 130 |
| abstract_inverted_index.important | 32 |
| abstract_inverted_index.interval. | 141 |
| abstract_inverted_index.mortality | 21 |
| abstract_inverted_index.objective | 53 |
| abstract_inverted_index.performed | 83 |
| abstract_inverted_index.reactions | 25 |
| abstract_inverted_index.reporting | 133 |
| abstract_inverted_index.(excluding | 118 |
| abstract_inverted_index.Conclusion | 246 |
| abstract_inverted_index.associated | 6 |
| abstract_inverted_index.classified | 158 |
| abstract_inverted_index.condition. | 296 |
| abstract_inverted_index.confidence | 140 |
| abstract_inverted_index.constitute | 27 |
| abstract_inverted_index.deviation: | 176 |
| abstract_inverted_index.frequently | 207, 264 |
| abstract_inverted_index.identified | 272 |
| abstract_inverted_index.implicated | 208 |
| abstract_inverted_index.modifiable | 33 |
| abstract_inverted_index.triggering | 292 |
| abstract_inverted_index.Gentamicin, | 234 |
| abstract_inverted_index.accelerated | 12 |
| abstract_inverted_index.eplerenone, | 235 |
| abstract_inverted_index.experienced | 168 |
| abstract_inverted_index.long‐term | 13 |
| abstract_inverted_index.physicians' | 285 |
| abstract_inverted_index.potentially | 294 |
| abstract_inverted_index.replacement | 188 |
| abstract_inverted_index.responsible | 290 |
| abstract_inverted_index.administered | 194 |
| abstract_inverted_index.candesartan, | 237 |
| abstract_inverted_index.corresponded | 91, 111 |
| abstract_inverted_index.antibacterial | 212 |
| abstract_inverted_index.comprehensive | 62, 248 |
| abstract_inverted_index.concomitantly | 193 |
| abstract_inverted_index.spontaneously | 71, 115 |
| abstract_inverted_index.antineoplastic | 227 |
| abstract_inverted_index.case–noncase | 85 |
| abstract_inverted_index.drug‐induced | 43, 65, 88 |
| abstract_inverted_index.hospitalization | 10 |
| abstract_inverted_index.spironolactone, | 236 |
| abstract_inverted_index.pharmacovigilance | 78, 253 |
| abstract_inverted_index.life‐threatening | 295 |
| abstract_inverted_index.anti‐inflammatory | 231 |
| abstract_inverted_index.renin–angiotensin | 224 |
| cited_by_percentile_year.max | 100 |
| cited_by_percentile_year.min | 94 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8899999856948853 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.92909641 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |